KLACID XL 500 XL 14 TAB; clarithromycin, antibacterials .
ACTIVE-INGREDIENT OF KLACID XL 500 XL 14 TAB
Clarithromycin 500 mg/tablet.
INDICATION OF KLACID XL 500 XL 14 TAB
Consideration should be given to official guidance on the appropriate use of antibacterial agents. Klacid XL or Clarithromycin 500 mg Modified Release Tablets are indicated in adults and children 12 years and older. Klacid XL or Clarithromycin 500 mg Modified Release Tablets are indicated for treatment of infections caused by susceptible organisms . Indications include : Lower respiratory tract infections for example, acute and chronic Bronchotitis , pneumonia. Upper respiratory tract infections for example, sinusitis, Pharyngitis . In skin and soft tissue infections of mild to moderate severity, for example folliculitis, cellulitis and erysioelas.
DOSAGE OF KLACID XL 500 XL 14 TAB
Follow all directions given to you by your pharmacist or doctor carefully . They may differ from the information contained in this leaflet
Ask your pharmacist or doctor for help if you do not understand the instructions on the box .
The recommended dose is : –
Adults: The usual recommended dosage of Klacid XL or Clarithromycin 500 mg Modified Release Tablets in adults is one 500 mg modified-release tablet daily to be taken with food. In more severe infections, the dosage can be increased to two 500 mg mofified-release tablets daily. The usual duration of treatment is 6 to 14 days. Children older than 12 years: As for adults. Children younger than 12 years: Use of Klacid XL or Clarithromycin 500 mg Modified Release Tablets are not recommended for children younger than 12 years. Clinical trials have been conducted using clarithromycin oeadiatric suspension in children 6 months to 12 years of age. Therefore, children under 12 years of age should use clarithromycin peadiatric suspension (granules for oral suspension). In patients with renal impairment with creatinine clearance less than 30 mL/min, the dosage of clarithromycin should be reduced by one-half, i.e. 250 mg once daily, or 250 mg twice daily in more severe infections. Treatment should be continued beyond 14 days in these patients. Because the tablet cannot be split, the dose cannot be reduced from 500 mg daily, Klacid XL or Clarithromycin 500 mg Modified Release Tablets should not be used in this patient population.
OVER-DOSAGE OF KLACID XL 500 XL 14 TAB
Reports indicate that the ingestion of large amounts of clarithromycin can be expected to produce gastrointestinal symptoms . One patient who had a history of bipolar disorder ingestedeight grams of clarithromycin and showed altered mental status , paranoid behavior , hypokalaemia and hypoxaemia . adverse reactions accompanying overdosage should be treated by the prompt elimination of unabsorbed drug and supportive measures . as with other macrolides , clarithromycin serum levels are not expected to be appreciably affected by haemodialysis or peritoneal dialysis .
CONTRA-INDICATION OF KLACID XL 500 XL 14 TAB
Klacid XL or Clarithromycin 500 mg Modified Release Tablets are conta-indicated in patients with known hypersensitivity to macrolide antibiotic drugs or any of its excipients . As the dose cannot be reduced from 500 mg daily, Klacid XL or Clarithromycin 500 mg Modified Release Tablets are conta-indicated in patients with creatinine clearance less than 30 mL/min. All other formulations may be used in this patient population. Concomitant administration of clarithromycin and any of the following drugs is contraindicated : astemizole , cisapride , primozide or terfenadine as this may result in QT prolongation and cardiac arrhythmias , including ventricular tachycardia , venticular fibnilation , and torsades de pointes . clarithromycin should not given to patients with history of QT prolongation or ventricular cardiac arrhythmia , including torsades de pointe. clarithromycin should not be used concomitantly with HMG-COA reductase inhibitors ( strains ) , lovestain or simvastain , due to the increased risk of rhabdomyolysis. Treatment with these agents should be discontinued during clarithromycin treatment. clarithromycin should not be given to patients with hypokalaemia ( risk prolongation of QT – time ) . clarithromycin should not be used in patients who suffer from severe hepatic failure in combination with renal impairment .
STORAGE OF KLACID XL 500 XL 14 TAB
Do not store above 30 °C Store in the original package.
PACK OF KLACID XL 500 XL 14 TAB
Carton box containing one strip 14 tablets with insert .
KLACID XL 500 XL 14 TAB MANUFACTURED BY
Kahira Pharma. & Chem. Ind. Co. Under License of. Abbott Laboratories -UK.